文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种新型微孔生物材料疫苗平台,可针对病毒感染产生持久的抗体介导免疫。

A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.

机构信息

Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ 07103, United States of America.

Tempo Therapeutics, 3030 Bunker Hill st., suite 104, San Diego, CA 92109, United States of America.

出版信息

J Control Release. 2024 Jun;370:570-582. doi: 10.1016/j.jconrel.2024.05.008. Epub 2024 May 11.


DOI:10.1016/j.jconrel.2024.05.008
PMID:38734312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11665867/
Abstract

Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized Microporous Annealed Particle (MAP) with aqueous solution containing target antigens. Upon administration of antigen loaded MAP (VaxMAP), the biomaterial reconstitution forms an instant antigen-loaded porous scaffold area with a sustained release profile to maximize humoral immunity. VaxMAP induced CD4 T follicular helper (Tfh) cells and germinal center (GC) B cell responses in the lymph nodes similar to Alum. VaxMAP loaded with SARS-CoV-2 spike protein improved the magnitude, neutralization, and duration of anti-receptor binding domain antibodies compared to Alum vaccinated mice. A single injection of Influenza specific HA1-loaded-VaxMAP enhanced neutralizing antibodies and elicited greater protection against influenza virus challenge than HA1-loaded-Alum. Thus, VaxMAP is a platform that can be used to promote adaptive immune cell responses to generate more robust neutralizing antibodies, and better protection upon pathogen challenge.

摘要

目前的抗原递送平台,如铝佐剂和纳米颗粒,不易调节,因此可能无法产生最佳的适应性免疫反应。我们通过将冻干的微孔退火颗粒(MAP)加载到含有目标抗原的水溶液中,创建了一种抗原递送平台。在给予负载抗原的 MAP(VaxMAP)后,生物材料重构形成具有持续释放特征的即时抗原负载多孔支架区域,以最大限度地提高体液免疫。VaxMAP 在淋巴结中诱导 CD4 滤泡辅助(Tfh)细胞和生发中心(GC)B 细胞反应,类似于铝佐剂。与接种铝佐剂的小鼠相比,负载 SARS-CoV-2 刺突蛋白的 VaxMAP 提高了抗体的效价、中和作用和持续时间。单次注射流感特异性 HA1 负载-VaxMAP 可增强中和抗体,并对流感病毒攻击产生更好的保护作用,优于 HA1 负载的铝佐剂。因此,VaxMAP 是一种可以用来促进适应性免疫细胞反应的平台,以产生更强大的中和抗体,并在病原体攻击时提供更好的保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/91dd2f59bd06/nihms-2040464-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/df1cd56c3098/nihms-2040464-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/924f6999b5c6/nihms-2040464-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/1aa8033d7f15/nihms-2040464-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/c92355807eee/nihms-2040464-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/a1eba3e5ed48/nihms-2040464-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/91dd2f59bd06/nihms-2040464-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/df1cd56c3098/nihms-2040464-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/924f6999b5c6/nihms-2040464-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/1aa8033d7f15/nihms-2040464-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/c92355807eee/nihms-2040464-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/a1eba3e5ed48/nihms-2040464-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732b/11665867/91dd2f59bd06/nihms-2040464-f0006.jpg

相似文献

[1]
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.

J Control Release. 2024-6

[2]
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.

bioRxiv. 2024-1-31

[3]
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

Cell Mol Immunol. 2022-2

[4]
Improved Humoral Immunity and Protection against Influenza Virus Infection with a 3d Porous Biomaterial Vaccine.

Adv Sci (Weinh). 2023-11

[5]
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.

Eur J Immunol. 2021-7

[6]
A decavalent composite mRNA vaccine against both influenza and COVID-19.

mBio. 2024-9-11

[7]
Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.

Vaccine. 2025-3-19

[8]
A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants.

PLoS Pathog. 2024-9

[9]
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

J Virol. 2024-9-17

[10]
Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2.

Acta Biomater. 2024-7-15

引用本文的文献

[1]
Nanomaterial Adjuvants for Veterinary Vaccines: Mechanisms and Applications.

Research (Wash D C). 2025-7-8

[2]
Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004-2023.

Front Immunol. 2024

本文引用的文献

[1]
A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates.

Nat Commun. 2023-11-4

[2]
Improved Humoral Immunity and Protection against Influenza Virus Infection with a 3d Porous Biomaterial Vaccine.

Adv Sci (Weinh). 2023-11

[3]
Engineering Immunomodulatory Biomaterials to Drive Skin Wounds toward Regenerative Healing.

Cold Spring Harb Perspect Biol. 2023-5-2

[4]
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity.

Sci Transl Med. 2022-7-20

[5]
Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?

Front Public Health. 2022-6-13

[6]
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.

Nat Mater. 2022-6

[7]
Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions.

Biomater Sci. 2022-3-15

[8]
Development of Tbet- and CD11c-expressing B cells in a viral infection requires T follicular helper cells outside of germinal centers.

Immunity. 2022-2-8

[9]
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.

Sci Immunol. 2022-2-4

[10]
A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.

Sci Immunol. 2021-12-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索